Ronald Peck has been appointed chief medical officer of New Haven, CT-based Arvinas (NASDAQ: ARVN). Peck most recently worked at cancer drug developer Tesaro where he was senior vice president of clinical research. His experience also includes posts at Kolltan Pharmaceuticals and Bristol-Myers Squibb (NYSE: BMY). Arvinas is developing drugs based on protein degradation, a cellular process for disposing of harmful proteins. In June, the company began a multi-year partnership with Bayer to develop products for both human health and agriculture.